MorphoSys AG
PLANEGG, GERMANY and MUNICH, GERMANY / ACCESSWIRE / July 21, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR), a commercial-stage biopharmaceutical company and a leader in antibody and protein technologies, will publish its results for the second quarter and first half 2021 on July 28, 2021 at 10:00pm CEST (4:00pm EDT).
MorphoSys' Management Board will host a conference call and webcast on July 29, 2021 at 2:00pm CEST (8:00am EDT) to present the second quarter and first half financial results 2021 and provide a further outlook for 2021.
The conference call will start with a presentation by the Management Board followed by a Q&A session. Following Board Members will be on the call:
- Jean-Paul Kress, M.D., Chief Executive Officer
- Sung Lee, Chief Financial Officer
- Roland Wandeler, Ph.D., Chief Operating Officer
- Malte Peters, M.D., Chief Research & Development Officer
A live webcast and slides will be made available at the Media and Investors section under Conferences on MorphoSys' website, www.morphosys.com .
Dial-in number for the conference call (2:00pm CEST, 8:00am EDT):
Germany: +49 69 201 744 220
For UK residents: +44 203 009 2470
For US residents: +1 877 423 0830
(all numbers reachable from any geography)
Participant PIN: 72989449#
Please dial in 10 minutes before the beginning of the conference.
A replay of the conference will also be available at the corporate website following the live event.
About MorphoSys
MorphoSys (FSE:MOR)(NASDAQ:MOR) is a biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for people living with cancer and autoimmune diseases. Based on its leading expertise in antibody and protein technologies, MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. In 2017, Tremfya (R) (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys' antibody technology to receive regulatory approval. In July 2020, the U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (R) (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma. Headquartered near Munich, Germany, the MorphoSys Group, including the fully owned U.S. subsidiaries MorphoSys US Inc. and Constellation Pharmaceuticals, Inc., has more than 750 employees. For more information visit www.morphosys.com or www.morphosys-us.com .
Monjuvi (R) is a registered trademark of MorphoSys AG.
Tremfya (R) is a registered trademark of Janssen Biotech, Inc.
Forward Looking Statements
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are that MorphoSys' expectations may be incorrect, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements, MorphoSys' reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys' Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.
For more information, please contact:
Media Contacts:
Thomas Biegi
Vice President
Tel.: +49 (0)89 / 899 27 26 079
thomas.biegi@morphosys.com
Investor Contacts:
Dr. Julia Neugebauer
Senior Director
Tel: +49 (0)89 / 899 27 179
julia.neugebauer@morphosys.com
Jeanette Bressi
Director, US Communications
Tel: +1 617 404 7816
jeanette.bressi@morphosys.com
Myles Clouston
Senior Director
Tel: +1 857 772 0240
myles.clouston@morphosys.com
SOURCE: MorphoSys AG
View source version on accesswire.com:
https://www.accesswire.com/656539/Invitation-to-MorphoSys-Second-Quarter-and-First-Half-2021-Results-Conference-Call-on-July-29-2021
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Air T Welcomes Creditor Support for Rex Acquisition11.11.2025 23:00:00 CET | Press release
MINNEAPOLIS, MINNESOTA / ACCESS Newswire / November 11, 2025 / Air T, Inc. (NASDAQ:AIRT) is pleased to announce that a majority of Rex's creditors-both in number and in value-have voted in favor of our bid to acquire Rex at the second meeting of creditors held on 11 November 2025. This strong endorsement reflects confidence in our vision for Rex and our commitment to regional aviation in Australia. We take our responsibilities under the proposed Deed of Company Arrangement seriously. We understand the Administrators intend to close the transaction by year-end, and we are working closely with all parties to ensure a smooth and timely completion. Air T is grateful for the support shown throughout this process and looks forward to finalizing the acquisition and beginning a new chapter for Rex and regional communities across Australia. NOTE REGARDING STAKEHOLDER QUESTIONS If you have questions related to this release or other Air T matters, please use our interactive Q&A capability, throug
MicroVision Announces Third Quarter 2025 Results11.11.2025 22:05:00 CET | Press release
REDMOND, WASHINGTON / ACCESS Newswire / November 11, 2025 / MicroVision, Inc. (NASDAQ:MVIS), a technology pioneer delivering advanced perception solutions in autonomy and mobility, today announced its third quarter 2025 results. Key Business and Operational Highlights Appointed 30-year industry veteran Glen DeVos as Chief Executive Officer, elevating automotive capabilities. Introduced next generation solid-state lidar sensor, MOVIA S, offering an energy-efficient and cost-effective short-range solution for a wide variety of automotive, industrial, and defense sector applications. Launched industry-disrupting Tri-Lidar Architecture solution, offering an alternative to the lidar industry's myopic focus on single sensor solutions. Executed agreement to acquire Scantinel Photonics, a German developer of long-range FMCW lidar, joining investment and strategic partners in advancing lidar-on-chip solution for commercial vehicle and passenger car markets. Established design office and testing
Climate Goals Threatened by Industrialised Animal Farming, Reveals Key International Study11.11.2025 15:20:00 CET | Press release
LONDON, UK / ACCESS Newswire / November 11, 2025 / A new study in Animals highlights that industrialized animal farming is one of the most powerful - yet persistently neglected - forces driving the climate and biodiversity crises. The analysis, "The Missing Target: Why Industrialized Animal Farming Must Be at the Core of the Climate Agenda," synthesizes evidence from 47 international studies and concludes that reducing livestock production and embracing plant-based food systems is essential for meeting global climate goals. Major Insights Across global research, livestock farming contributes an estimated 12-20% of all greenhouse gas emissions annually, with the most comprehensive studies yielding the highest figures. The most modern accounting methods, which include the impacts of deforestation, bottom trawling and cooling effects from certain atmospheric pollutants, reveal that 52% of present-day global warming is attributable to animal agriculture. Animal agriculture occupies over 80
Resin Solutions Announces Commencement of up to $100 Million Global HTPB Production Expansion Initiative11.11.2025 15:00:00 CET | Press release
EXTON, PA / ACCESS Newswire / November 11, 2025 / Resin Solutions, Exton, PA, a portfolio company of Pacific Avenue Capital Partners, announced a multi-phase production capacity expansion initiative for its hydroxyl-terminated polybutadiene ("HTPB") product line, Poly bd®. Resin Solutions has begun the initial expansion phase, which includes debottlenecking initiatives and major capital investments at the company's Channelview, Texas and Ravenna, Italy facilities, which would expand existing capacity to meet expected additional demand for critical U.S. National Security Programs. In addition, the Resin Solutions Board has commenced a scoping and feasibility assessment to support additional greenfield capacity expansion in the United States and Europe. The Board of Resin Solutions, with support from Pacific Avenue Capital Partners, has authorized investment of up to $100 million to ensure Resin Solutions remains able to serve growing customer demand for HTPB in its aerospace, defense, a
MicroVision Collaborates with Leading Photonics Ecosystem to Acquire FMCW Lidar Business10.11.2025 22:05:00 CET | Press release
REDMOND, WA / ACCESS Newswire / November 10, 2025 / MicroVision, Inc. (NASDAQ:MVIS), a technology pioneer delivering advanced perception solutions in autonomy and mobility, today announced that it had entered into an agreement to acquire the business and assets of Scantinel Photonics GmbH, a developer of 1550nm frequency-modulated continuous wave, or FMCW, lidar technology targeted for initial application in the commercial vehicle market. In connection with the acquisition, MicroVision is collaborating with certain funding and strategic partners to accelerate productization and commercial opportunities. Scantinel Photonic's core technology was developed with financial backing and key support from Zeiss Group, a German manufacturer of optical systems and optoelectronics; Scania, a Swedish commercial trucking OEM; and PhotonVentures, a deep tech venture capital firm purely focused on the key enabling technology of integrated photonics and a strategic partner of PhotonDelta, a Dutch distr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom